Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

Jill A. Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Augustina Ogbonnaya, Michael Eaddy, Robert J. Fram, Douglas V. Faller, Vamsi Kota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0% of patients had ≥1 inpatient admission; 85.7% had ≥1 AML-related admission, and 42.6% had ≥1 non-AML-related admission. During inpatient admissions, 39.2% of patients had ≥1 intensive care unit (ICU) admission, with 20.7% having ≥1 AML-related ICU admission, and 27.8% having ≥1 non-AML-related ICU admission. Total mean per-patient per-month (PPPM) costs over the follow-up period were $25,243 (SD: $21,909), with costs from Year 1 ($27,756 [SD: $22,121]) more than double those in Year 2 ($12,953 [SD: $26,334]) following AML diagnosis. The majority of total costs were medical ($24,512 PPPM [SD: $21,704]), which included inpatient admissions ($6548 PPPM [SD: $10,777]), other outpatient visits ($5021 PPPM [SD: $7997]), supportive care ($3640 PPPM [SD: $5589], and chemotherapy administration ($2029 PPPM [SD: $2345]). Healthcare costs of treated elderly AML patients are substantial, particularly in the first year following diagnosis. Further research is needed to understand factors contributing to high costs in various settings of care for elderly AML patients.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalLeukemia Research
Volume71
DOIs
StatePublished - Aug 1 2018

Fingerprint

Acute Myeloid Leukemia
Economics
Intensive Care Units
Costs and Cost Analysis
Inpatients
Myeloid Leukemia
Health Care Costs
Drug Therapy
Patient Admission
Outpatients
Stem Cells
Databases
Transplants

Keywords

  • Acute myeloid leukemia
  • Cost
  • Elderly
  • Healthcare burden
  • Healthcare utilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. / Bell, Jill A.; Galaznik, Aaron; Farrelly, Eileen; Blazer, Marlo; Murty, Sharanya; Ogbonnaya, Augustina; Eaddy, Michael; Fram, Robert J.; Faller, Douglas V.; Kota, Vamsi.

In: Leukemia Research, Vol. 71, 01.08.2018, p. 27-33.

Research output: Contribution to journalArticle

Bell, JA, Galaznik, A, Farrelly, E, Blazer, M, Murty, S, Ogbonnaya, A, Eaddy, M, Fram, RJ, Faller, DV & Kota, V 2018, 'Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States', Leukemia Research, vol. 71, pp. 27-33. https://doi.org/10.1016/j.leukres.2018.06.010
Bell, Jill A. ; Galaznik, Aaron ; Farrelly, Eileen ; Blazer, Marlo ; Murty, Sharanya ; Ogbonnaya, Augustina ; Eaddy, Michael ; Fram, Robert J. ; Faller, Douglas V. ; Kota, Vamsi. / Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. In: Leukemia Research. 2018 ; Vol. 71. pp. 27-33.
@article{f76696974c304ca0ba47a536913842ad,
title = "Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States",
abstract = "This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0{\%} of patients had ≥1 inpatient admission; 85.7{\%} had ≥1 AML-related admission, and 42.6{\%} had ≥1 non-AML-related admission. During inpatient admissions, 39.2{\%} of patients had ≥1 intensive care unit (ICU) admission, with 20.7{\%} having ≥1 AML-related ICU admission, and 27.8{\%} having ≥1 non-AML-related ICU admission. Total mean per-patient per-month (PPPM) costs over the follow-up period were $25,243 (SD: $21,909), with costs from Year 1 ($27,756 [SD: $22,121]) more than double those in Year 2 ($12,953 [SD: $26,334]) following AML diagnosis. The majority of total costs were medical ($24,512 PPPM [SD: $21,704]), which included inpatient admissions ($6548 PPPM [SD: $10,777]), other outpatient visits ($5021 PPPM [SD: $7997]), supportive care ($3640 PPPM [SD: $5589], and chemotherapy administration ($2029 PPPM [SD: $2345]). Healthcare costs of treated elderly AML patients are substantial, particularly in the first year following diagnosis. Further research is needed to understand factors contributing to high costs in various settings of care for elderly AML patients.",
keywords = "Acute myeloid leukemia, Cost, Elderly, Healthcare burden, Healthcare utilization",
author = "Bell, {Jill A.} and Aaron Galaznik and Eileen Farrelly and Marlo Blazer and Sharanya Murty and Augustina Ogbonnaya and Michael Eaddy and Fram, {Robert J.} and Faller, {Douglas V.} and Vamsi Kota",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.leukres.2018.06.010",
language = "English (US)",
volume = "71",
pages = "27--33",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

AU - Bell, Jill A.

AU - Galaznik, Aaron

AU - Farrelly, Eileen

AU - Blazer, Marlo

AU - Murty, Sharanya

AU - Ogbonnaya, Augustina

AU - Eaddy, Michael

AU - Fram, Robert J.

AU - Faller, Douglas V.

AU - Kota, Vamsi

PY - 2018/8/1

Y1 - 2018/8/1

N2 - This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0% of patients had ≥1 inpatient admission; 85.7% had ≥1 AML-related admission, and 42.6% had ≥1 non-AML-related admission. During inpatient admissions, 39.2% of patients had ≥1 intensive care unit (ICU) admission, with 20.7% having ≥1 AML-related ICU admission, and 27.8% having ≥1 non-AML-related ICU admission. Total mean per-patient per-month (PPPM) costs over the follow-up period were $25,243 (SD: $21,909), with costs from Year 1 ($27,756 [SD: $22,121]) more than double those in Year 2 ($12,953 [SD: $26,334]) following AML diagnosis. The majority of total costs were medical ($24,512 PPPM [SD: $21,704]), which included inpatient admissions ($6548 PPPM [SD: $10,777]), other outpatient visits ($5021 PPPM [SD: $7997]), supportive care ($3640 PPPM [SD: $5589], and chemotherapy administration ($2029 PPPM [SD: $2345]). Healthcare costs of treated elderly AML patients are substantial, particularly in the first year following diagnosis. Further research is needed to understand factors contributing to high costs in various settings of care for elderly AML patients.

AB - This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0% of patients had ≥1 inpatient admission; 85.7% had ≥1 AML-related admission, and 42.6% had ≥1 non-AML-related admission. During inpatient admissions, 39.2% of patients had ≥1 intensive care unit (ICU) admission, with 20.7% having ≥1 AML-related ICU admission, and 27.8% having ≥1 non-AML-related ICU admission. Total mean per-patient per-month (PPPM) costs over the follow-up period were $25,243 (SD: $21,909), with costs from Year 1 ($27,756 [SD: $22,121]) more than double those in Year 2 ($12,953 [SD: $26,334]) following AML diagnosis. The majority of total costs were medical ($24,512 PPPM [SD: $21,704]), which included inpatient admissions ($6548 PPPM [SD: $10,777]), other outpatient visits ($5021 PPPM [SD: $7997]), supportive care ($3640 PPPM [SD: $5589], and chemotherapy administration ($2029 PPPM [SD: $2345]). Healthcare costs of treated elderly AML patients are substantial, particularly in the first year following diagnosis. Further research is needed to understand factors contributing to high costs in various settings of care for elderly AML patients.

KW - Acute myeloid leukemia

KW - Cost

KW - Elderly

KW - Healthcare burden

KW - Healthcare utilization

UR - http://www.scopus.com/inward/record.url?scp=85048896177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048896177&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2018.06.010

DO - 10.1016/j.leukres.2018.06.010

M3 - Article

C2 - 29944984

AN - SCOPUS:85048896177

VL - 71

SP - 27

EP - 33

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -